SynAgile introduced the finishing touch of a Section 2 scientific trial comparing DopaFuse, its noninvasive device for
Introduction In the United States (US), more than two-thirds of the population takes at least
Omega Therapeutics CAMBRIDGE, Mass., Jan. 17, 2023 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq: OMGA)
STOCKHOLM, SE / ACCESSWIRE / January 11, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB
49% objective response rate (ORR) in heavily pre-treated patients who were naïve to prior CAR-T,
Pharvaris N.V. Primary endpoint met, substantially reducing HAE attack symptoms All secondary endpoints met PHVS416